Peijiang Pan
Biographic Data
| ID | 8938769 |
|---|---|
| NAME | Peijiang Pan |
| GIVEN NAMES | Peijiang |
| FAMILY NAME | Pan |
| SIGNATURE | PAN P |
| AFFILIATIONS | Guangxi Medical University |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Impact of first-line antiretroviral therapy choice on adverse drug reactions in children with HIV infection
Antiretroviral therapy (ART) is essential in managing children with human immunodeficiency virus (HIV) infection, but is often complicated by adverse drug reactions (ADRs), which can significantly impact therapeutic outcomes. This study investigates ADRs in 375 children with HIV receiving zidovudine (AZT)- or abacavir (ABC)-based ART regimens, using Kaplan-Meier, Cox regression analyses to evaluate ADR incidences, and propensity score matching (P…
No prominent works on this page.
Impact of first-line antiretroviral therapy choice on adverse drug reactions in children with HIV infection
Antiretroviral therapy (ART) is essential in managing children with human immunodeficiency virus (HIV) infection, but is often complicated by adverse drug reactions (ADRs), which can significantly impact therapeutic outcomes. This study investigates ADRs in 375 children with HIV receiving zidovudine (AZT)- or abacavir (ABC)-based ART regimens, using Kaplan-Meier, Cox regression analyses to evaluate ADR incidences, and propensity score matching (P…
Abacavir (1 work) · Adverse effect (1 work) · Antiretroviral therapy (1 work) · Atazanavir (1 work) · Cohort (1 work) · Cohort study (1 work) · Confidence interval (1 work) · Hazard ratio (1 work) · HIV Research and Treatment (1 work) · HIV/AIDS drug development and treatment (1 work)